Mesa Laboratories (NASDAQ:MLAB) Releases Earnings Results, Misses Estimates By $1.54 EPS

Mesa Laboratories (NASDAQ:MLAB) issued its earnings results on Monday. The medical instruments supplier reported $0.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.29 by ($1.54), FiscalAI reports. The company had revenue of $62.34 million during the quarter, compared to analyst estimates of $62.20 million. Mesa Laboratories had a return on equity of 22.72% and a net margin of 1.92%.

Here are the key takeaways from Mesa Laboratories’ conference call:

• Organic revenue growth accelerated to 2.6% in Q2 from 1% in Q1, and was about 5% excluding Clinical Genomics. Sterilization and Disinfection Control grew in the mid-teens and Calibration Solutions about 3.5%, while Biopharmaceutical Development declined 8.2% due to export-control delays and shipments that moved into Q3.
• Fiscal 2027 guidance calls for $250 million–$255 million in revenue and $66 million–$68 million in adjusted EBITDA, implying EBITDA growth of 5%–8% even as revenue grows 0%–2%. Management said the outlook includes Clinical Genomics’ revenue reset and restructuring-plan reinvestments, and was set conservatively.
• SDC grew 14.6% organically in Q2, largely reflecting a comparison with prior-year delivery delays, and its trailing 12-month revenue reached a record $103.9 million. However, a key product line responsible for much of the past-due backlog is only partially fixed, leaving a significant delivery-reliability issue unresolved.
• Mesa is restructuring Clinical Genomics to focus on pharmacogenomics, oncology, and high-utilization customer accounts; revenue is expected to be lower, but management expects profitability to improve and cited multiyear renewals from its three largest customers. The company expects about $9.3 million in annualized gross cost savings, reinvesting $4.3 million for a net reduction of about $5 million.
• Mesa repaid $20.1 million of debt in the first half and ended the quarter at 1.75x net leverage, within its target range. The board also authorized share repurchases of up to $40 million through December 2028, while management said debt reduction and investment in higher-return businesses remain priorities.

Mesa Laboratories Price Performance

Shares of MLAB traded down $0.43 on Monday, hitting $127.82. The company’s stock had a trading volume of 118,371 shares, compared to its average volume of 140,604. The company has a market capitalization of $715.79 million, a PE ratio of 152.17 and a beta of 1.08. Mesa Laboratories has a fifty-two week low of $69.51 and a fifty-two week high of $144.35. The company has a 50 day moving average price of $128.30 and a 200 day moving average price of $104.95. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.79 and a quick ratio of 1.32.

Mesa Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 15th. Stockholders of record on Monday, November 30th will be issued a $0.16 dividend. This represents a $0.64 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend is Monday, November 30th. Mesa Laboratories’s payout ratio is presently 76.19%.

Insider Activity at Mesa Laboratories

In other Mesa Laboratories news, CEO Siddhartha Kadia purchased 7,093 shares of the company’s stock in a transaction that occurred on Thursday, August 13th. The stock was purchased at an average cost of $112.80 per share, with a total value of $800,090.40. Following the acquisition, the chief executive officer directly owned 7,093 shares of the company’s stock, valued at approximately $800,090.40. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, Director John Sullivan sold 7,093 shares of Mesa Laboratories stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $112.80, for a total value of $800,090.40. Following the completion of the transaction, the director owned 17,834 shares of the company’s stock, valued at approximately $2,011,675.20. The trade was a 28.46% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 2.80% of the company’s stock.

Analyst Upgrades and Downgrades

MLAB has been the topic of several recent analyst reports. Weiss Ratings raised Mesa Laboratories from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, October 8th. Wall Street Zen upgraded Mesa Laboratories from a “buy” rating to a “strong-buy” rating in a research report on Saturday, October 3rd. Finally, Wells Fargo & Company increased their price objective on Mesa Laboratories from $94.00 to $110.00 and gave the stock an “equal weight” rating in a research note on Friday, August 14th. Three research analysts have rated the stock with a Hold rating. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $110.00.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc develops and manufactures products used for quality control, monitoring, and measurement in healthcare, pharmaceutical, industrial, and other regulated applications. The company’s offerings are designed to help customers verify the performance of processes, equipment, and environmental conditions.

Mesa Laboratories’ product portfolio includes sterilization assurance products, such as biological indicators and related monitoring systems, as well as instruments and consumables used in healthcare and laboratory settings.